{
  "ticker": "ALLO",
  "company_name": "Allogene Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06500273",
      "title": "Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Large B-cell Lymphoma",
      "start_date": "2024-06-18",
      "completion_date": "2031-08-24",
      "enrollment": 0,
      "sponsor": "Allogene Therapeutics"
    }
  ],
  "summary": {
    "total_trials": 1,
    "by_phase": {
      "PHASE2": 1
    },
    "by_status": {
      "RECRUITING": 1
    },
    "active_trials": 1,
    "completed_trials": 0,
    "conditions": [
      "Large B-cell Lymphoma"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:43:40.353495",
    "search_query": "Allogene Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Allogene+Therapeutics,+Inc."
  }
}